<DOC>
	<DOC>NCT01009580</DOC>
	<brief_summary>This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.</brief_summary>
	<brief_title>Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months Subjects on premixed human or analogue insulin or selfmixed insulin regimen, containing 2040 % fast/rapidacting component, once daily (OD) or twice daily (BID), with or without oral antidiabetic drugs) (OADs) (metformin, sulphonylurea (SU), glinides, alphaglucosidase inhibitor, DPP4 (dipeptidyl peptidase4) inhibitor and pioglitazone), for at least 3 months before Visit 1 HbA1c 7.010.0 % (both inclusive) by central laboratory analysis Body Mass Index (BMI) below or equal to 40.0 kg/m^2 Treatment with other insulin regimens than those listed in key inclusion criterion no. 2 within 3 months Treatment with rosiglitazone or glucagonlike peptide1 (GLP1) receptor agonists (exenatide, liraglutide) within 3 months prior to visit 1 Cardiovascular disease within the last 6 months prior to visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least 180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg) Pregnancy, breastfeeding, the intention of becoming pregnant or not using adequate contraceptive measures according to local requirements Cancer and medical history of cancer (except basal cell skin cancer and squamous cell skin cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>